Response to anti-EGFR therapy in patients with BRAF non-V600 mutant metastatic colorectal cancer

PURPOSE: While mutations in BRAF in metastatic colorectal cancer (mCRC) most commonly occur at the V600 amino acid, with the advent of next-generation sequencing, non-V600 BRAF mutations are increasingly identified in clinical practice. It is unclear whether these mutants, like BRAF V600E, confer re...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Clin Cancer Res
Главные авторы: Yaeger, Rona, Kotani, Daisuke, Mondaca, Sebastián, Parikh, Aparna, Bando, Hideaki, Van Seventer, Emily, Taniguchi, Hiroya, Zhao, HuiYong, Thant, Claire, de Stanchina, Elisa, Rosen, Neal, Corcoran, Ryan B., Yoshino, Takayuki, Yao, Zhan, Ebi, Hiromichi
Формат: Artigo
Язык:Inglês
Опубликовано: 2019
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6891165/
https://ncbi.nlm.nih.gov/pubmed/31515458
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-2004
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы